ArticleScientific reports2025
Plasma microRNAs and chemokines as biomarkers for rejection in liver transplantation with score verification and tissue correlation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The use of biomarkers in liver transplantation (LT) may be useful for the noninvasive assessment of T-cell-mediated rejection (TCMR). This study aimed to: (1) determine if changes in circulating microRNAs (miRNAs) in rejector patients reflect those at the tissue level; (2) assess a biomarker score (including miRNAs 155-5p, 181a-5p, and CXCL-10) in an independent cohort and (3) evaluate the score's utility in detecting other LT-related complications. A prospective cohort of 151 LT recipients was followed during the first year after surgery. Patients with abnormal liver function tests (LFTs) underwent liver biopsy (LB) to rule out TCMR. Plasma samples were collected at predefined time points to analyse miRNAs and chemokines and their ability to predict and diagnose TCMR. To correlate plasma biomarkers with their tissue expression, 27 liver tissue samples (9 with normal LFTs and 18 with TCMR) were selected. Forty patients were diagnosed with TCMR. Circulating miRNAs (155-5p and 122-5p) reflected tissue-level changes in TCMR (p < 0.001, 3.3-fold increase for miR-155 and 2.3 for miR-122). Additionally assessed plasma miRNA 885-5p and chemokines CXCL-9 and CXCL-11, were also significantly elevated in TCMR but did not improve the performance of our previously biomarker score for TCMR (AUROC 0.94 for prediction, 0.99 for diagnosis). In conclusion, we confirmed in an independent cohort the performance of the score based on miR-155-5p, miR-181a-5p, and CXCL10. The correlation between circulating miRNAs and liver tissue expression underscores their value for predicting and diagnosing TCMR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.